Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL

Death Receptor Agonists as a Targeted Therapy for Cancer

(2010) J. Wiezorek et al.   CLINICAL CANCER RESEARCH

Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation

(2010) K Mizrahi et al.   LEUKEMIA

New insights into apoptosis signaling by Apo2L/TRAIL

(2010) F Gonzalvez et al.   ONCOGENE

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-  converting enzyme (TACE)

(2009) M. Hiasa et al.   BLOOD

Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis

(2009) Paola Secchiero et al.   CURRENT OPINION IN HEMATOLOGY

Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1

(2009) Patricia Moretto et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

TRAILing death in cancer

(2009) Gregory Mellier et al.   MOLECULAR ASPECTS OF MEDICINE

Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells

(2008) Barbara Zdzisińska et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors

(2008) E. David et al.   CLINICAL CANCER RESEARCH

Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma

(2008) Ken-ichi Kitazoe et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Emerging roles of ADAM and ADAMTS metalloproteinases in cancer

(2007) N. Rocks et al.   BIOCHIMIE